Harnessing endogenous peptide compounds as potential therapeutics for severe influenza.

Alison C WestChristopher M HarpurMélanie A Le PageMaggie LamChristopher HodgesLauren K ElyAndrew J GearingMichelle D Tate

Published in: The Journal of infectious diseases (2023)

These findings provide preclinical evidence that therapeutic LAT9997 treatment limits viral burden and characteristic features of severe influenza, including hyperinflammation and lung damage.

Keyphrases

early onset
sars cov
small molecule
cell therapy
drug induced
risk factors
stem cells
machine learning
risk assessment
mesenchymal stem cells
replacement therapy
bone marrow
climate change